This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Farletuzumab

Eisai Co., Ltd.

Drug Names(s): MORAb-003

Description: MORAb-003 is a monoclonal antibody that targets the folate receptor alpha (FRA), a target over-expressed in over 90% of ovarian cancers and a number of other solid tumors. The antibody works via suppression of FRA-mediated signal transduction and induces tumor-specific cytotoxicity by both antibody dependent cellular and complement mediated immune-effector mechanisms.

Deal Structure: In April 2007, Eisai completed the acquisition of Morphotek.

Morphotek and Eurofarm
In October 2016, Morphotek announced that it signed an exclusive licensing agreement with Eurofarma Laboratrios to develop and commercialize farletuzumab (MORAb-003) in Latin America. In exchange, Morphotek will receive an upfront payment, scheduled development and sales milestone payments, and other fees. Additionally, Morphotek will receive royalties from commercial sales of farletuzumab in Latin America. Morphotek will supply Eurofarma with clinical and commercial materials at an agreed-upon transfer price; Eurofarma has the option to assume responsibility for filling and labeling farletuzumab vials. Morphotek retains all rights to develop and commercialize farletuzumab in regions outside of Latin America.

Partners: PDL BioPharma, Inc. Eurofarma


Farletuzumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug